92,157
distinct stop-gain variants catalogued across ClinVar
A measurable molecular landscape for programme discovery
A category becoming real
The field has moved from possibility to disciplined execution.
Suppressor tRNA has reached a new stage of external validation. The differentiator now is not whether readthrough can occur, but whether candidate design, disease context, delivery and safety are integrated with enough discipline to produce durable programmes.
7,811
genes represented in the stop-gain landscape
A platform opportunity extending across many disease areas
4 gates
charging, transcript context, delivery and native-stop safety
The operating framework guiding candidate quality
India-first
population-aware evidence and development strategy
Domestic origination capability built for global standards
The molecular problem
The cell reaches “stop” too early
A nonsense mutation inserts an early stop signal into a protein-coding message. The ribosome leaves before the protein is complete, often reducing or eliminating a protein the cell needs.
The KritRNA approach
Reprogramme translation to continue
Engineered suppressor tRNAs can recognise selected premature stop codons and deliver an amino acid, allowing the ribosome to continue toward a full-length protein. KritRNA is building the design and evidence system required to make that possibility precise, programmable and disease-relevant.
Discover KritRNA
Different perspectives. One scientific mission.
KritRNA connects molecular science, therapeutic design, company building and patient-centred communication within one focused platform.
Families & advocates
Understand how premature stop codons interrupt protein production and why suppressor tRNA offers a new route toward restoration.
Explore the science in plain language →Scientists & development partners
Examine the molecular logic, dual-engine architecture, experimental strategy and collaboration opportunities behind the platform.
Enter the platform →Investors & strategic partners
Review the shared-mechanism thesis, development strategy, programme logic and India-built biotechnology opportunity.
View the investment thesis →Builders of the company
Join a founding-stage team working across computation, molecular biology, operations and scientific communication.
Explore open roles →The platform
Design the molecule. Model the system.
KritRNA is developing two connected engines that transform a target nonsense mutation into a biologically constrained, experimentally testable suppressor tRNA shortlist.
Engine 01 · suppressor-tRNA design
Candidate generation and ranking
Sequence design, processing and identity constraints, structure and thermodynamics, kinetic context, normal-stop risk, explainable scoring and Pareto selection.
Engine 02 · translation small-world
System-level consequence modelling
A mechanistic network connecting initiation, elongation, termination, ribosome traffic, NMD, rescue, stress signalling, folding and protein output.
India-first biotechnology
Built in India. Designed for global science.
KritRNA is creating India-owned capability in suppressor tRNA therapeutics, computational translation biology and evidence-driven drug discovery—while building to global scientific and regulatory standards.
→Scientific ownership from India
→β-thalassemia as an India-priority programme
→Evidence generated through formal collaborations
→Global scientific and regulatory standards
Initial research focus
Three programmes. One programmable modality.
Our first programmes test the platform across hematology, neuromuscular disease and oncology.
Hematology · India-priority
β-Thalassemia
Design suppressor-tRNA candidates for selected HBB nonsense-mutation contexts and restore β-globin production.
Current milestone
Program definition
Next: Candidate design and in-vitro assay specification
Neuromuscular
Duchenne muscular dystrophy
Design suppressor-tRNA candidates for selected DMD premature-stop contexts and restore full-length dystrophin.
Current milestone
Program definition
Next: Candidate design and reporter-assay specification
Oncology
p53-deficient cancer
Explore suppressor-tRNA strategies for selected TP53 nonsense mutations with the aim of restoring full-length p53 protein and tumour-suppressor function.
Current milestone
Program definition
Next: Mutation prioritisation and disease-relevant functional-assay planning
The meaning of KritRNA
Created with purpose.
Engineered to continue.
KritRNA draws its name from कृ (kṛ), the Sanskrit root meaning “to make, create or act,” and tRNA—the molecular adaptor that helps translate genetic information into protein. Together, the name means tRNA created with purpose: engineered to recognise selected premature stop codons and help translation continue toward a full-length protein.